AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
A 40.5% remission rate in a phase‑2 trial could reshape treatment hopes for Crohn's disease patients.
Evidence dossier
Intelligence passport
Measured timeline
Sources (5)
-
-
-
Subcutaneous Risankizumab Induction Improved Outcomes in Crohn's DiseaseMedPage Today · 13h ago
-
AbbVie ABBV-466 Achieves 40.5% Crohn's Remissiongrafa.com · 13h ago
-
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trialFierce Biotech · 13h ago
The brief
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: A 40.5% remission rate in a phase‑2 trial could reshape treatment hopes for Crohn's disease patients.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The improvement signals a tangible shift in therapeutic outcomes, offering a concrete reason for optimism among those facing limited options. The design builds on previous IBD findings presented at UEGW 2026, where Skyrizi and RINVOQ showed long‑term benefits.
Investing News Network detailed the trial results, while Fierce Biotech highlighted the superiority claim. The next step is determining whether larger phase‑3 studies will confirm these findings and how regulators will respond, leaving the path to market approval open.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (50% supported) Updated 2h ago.
Quick answers
What remission rate did the phase‑2 trial report?
The trial reported a 40.5% endoscopic remission rate for participants receiving ABBV-466.
How does ABBV-466 compare with Skyrizi in the trial?
ABBV-466 achieved higher remission rates than Skyrizi, indicating better efficacy in the phase‑2 comparison.
What are the next steps for ABBV-466 development?
Further clinical testing, likely phase‑3 trials, is needed to confirm efficacy and safety before regulatory review.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
FDA approves first new Parkinson’s drug class in half a century
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Apogee execs join Paragon after AbbVie buyout to scale R&D and company creation engine
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab’s phase‑2 ovarian‑cancer data boost its ADC platform and threaten AbbVie’s Elahere market share
Inside the study for a remedy to fight Congo’s deadliest Ebola outbreak
DR Congo’s massive Obeldesivir trial aims to halt the deadliest Ebola outbreak yet
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
New Parkinson’s drug approved in the US: What does it do differently?
AbbVie’s first‑in‑class Parkinson’s pill JUVMO lands FDA approval, yet insiders warn sales will crawl despite a $8.7 billion buyout.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.